Oxford virus trial offers hope for elderly

Updated October 26 2020 - 7:46pm, first published 7:43pm
Oxford-AstraZeneca's vaccine reportedly triggered antibodies and T-cells in older age groups.
Oxford-AstraZeneca's vaccine reportedly triggered antibodies and T-cells in older age groups.

The COVID-19 vaccine being developed by the University of Oxford produces an immune response in both elderly and young people and adverse reactions were lower among the elderly, British drug maker AstraZeneca says.

Subscribe now for unlimited access.

$0/

(min cost $0)

or signup to continue reading

See subscription options

Get the latest Canberra news in your inbox

Sign up for our newsletter to stay up to date.

We care about the protection of your data. Read our Privacy Policy.